Related references
Note: Only part of the references are listed.Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: from bench to bedside
Munira Shabbir et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Flow Cytometry Can Diagnose Classical Hodgkin Lymphoma in Lymph Nodes With High Sensitivity and Specificity
Jonathan R. Fromm et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma
Alfons Navarro et al.
BLOOD (2009)
Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas
Cecile Meier et al.
MODERN PATHOLOGY (2009)
Effects of the JAK2 Inhibitor, AZ960, on Pim/BAD/BCL-xL Survival Signaling in the Human JAK2 V617F Cell Line SET-2
Joseph M. Gozgit et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Treatment of Hodgkin lymphoma: the past, present, and future
Andrew M. Evens et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders
Elizabeth O. Hexner et al.
BLOOD (2008)
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials
A. Pardanani
LEUKEMIA (2008)
Novel small-molecule therapy of Hodgkin lymphoma
D. Buglio et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Expression of bcl2 family proteins and active caspase 3 in classical Hodgkin's lymphomas
Maria Bai et al.
HUMAN PATHOLOGY (2007)
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Ross L. Levine et al.
NATURE REVIEWS CANCER (2007)
Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation
MA Weniger et al.
ONCOGENE (2006)
Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma
I Melzner et al.
LEUKEMIA (2006)
Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2
S Joos et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
STAT3 is constitutively activated in Hodgkin cell lines
D Kube et al.
BLOOD (2001)
Share Paper
